DGAP-Adhoc: Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act) Epigenomics AG successfully completes private placement of newly issued shares

Epigenomics AG / Key word(s): Capital Increase

29.10.2013 23:44

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Not for distribution in the United States

Berlin, Germany, October 29, 2013 - Today the Executive Board of
Epigenomics AG (Frankfurt Prime Standard: ECX;ISIN: DE000A1K0516) with the
approval of the Supervisory Board has resolved on the increase of the
Company's share capital by EUR 660,260.00 from the authorized capital
2013/I against contribution in cash.The resolution follows a private
placement of 660,260 newly issued shares with institutional investors in
Europe and the U.S.Among others, the owners of Polymedco, Inc.,
Epigenomics' commercialization partner in the U.S., participated in the
transaction.

The issue price has been set at EUR 4.993 per share. This equals the
volume-weighted average Xetra price during the period of the last three
trading days before today's date.The preemptive rights of the shareholders
were excluded. Gross proceeds from this to Epigenomics amounted EUR 3.3 m.
Upon registration of the capital increase with the commercial register
('Handelsregister'), the Company's share capital will increase to EUR
12,996,387.

Epigenomics AG intends to use the net proceeds from this offering to
finance its current operations and to build and strengthen the distribution
capacities for its lead product Epi proColon(R), a blood-based test for the
detection of colorectal cancer.

-End of Ad hoc-

Disclaimer

This publication is not an offer of any securities for sale or a
solicitation of an offer topurchase any securities.

This document is not an offer of securities for sale or a solicitation of
an offer to purchase securities in the United States. The shares of
Epigenomics AG (the 'Shares') have not beenregistered under the U.S.
Securities Act of 1933, as amended (the 'Securities Act') and maynot be
offered or sold in the United States unless registered under the Securities
Act orpursuant to an exemption from such registration. There will be no
public offering of the Sharesin the United States and the Shares will not
be registered under the Securities Act.

Contact:

Epigenomics AG

Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements
involve certain known and unknown risks, uncertainties and other factors
which could cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Epigenomics AG is providing this communication
as of this date and does not undertake to update any forward-looking
statements contained herein as a result of new information, future events
or otherwise.

The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology which
may be sold at some future time in the U.S. have not been established.

---------------------------------------------------------------------------

Language: English
Company: Epigenomics AG
Kleine Präsidentenstraße 1
10178 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir@epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A1K0516
WKN: A1K051
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of Announcement DGAP News-Service

---------------------------------------------------------------------------